Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Muir, S.W.; Harrow, C.; Dawson, J.; Lees, K.R.; Weir, C.J.; Sattar, N.; Walters, M.R. (2008)
Publisher: American Heart Association
Languages: English
Types: Article
Subjects: R1

Background and Purpose: Elevated serum uric acid level is associated with poor outcome and increased risk of recurrent events after stroke. The xanthine oxidase inhibitor allopurinol lowers uric acid but also attenuates expression of inflammatory adhesion molecules in murine models, reduces oxidative stress in the vasculature, and improves endothelial function. We sought to investigate whether allopurinol alters expression of inflammatory markers after acute ischemic stroke.

\ud \ud

Methods: We performed a randomized, double-blind, placebo-controlled trial to investigate the safety, tolerability, and effect of 6 weeks’ treatment with high- (300 mg once a day) or low- (100 mg once a day) dose allopurinol on levels of uric acid and circulating inflammatory markers after ischemic stroke.

\ud \ud

Results: We enrolled 50 patients with acute ischemic stroke (17, 17, and 16 in the high, low, and placebo groups, respectively). Mean (±SD) age was 70 (±13) years. Groups had similar characteristics at baseline. There were no serious adverse events. Uric acid levels were significantly reduced at both 7 days and 6 weeks in the high-dose group (by 0.14 mmol/L at 6 weeks, P=0.002). Intercellular adhesion molecule-1 concentration (ng/mL) rose by 51.2 in the placebo group, rose slightly (by 10.6) in the low-dose allopurinol group, but fell in the high-dose group (by 2.6; difference between groups P=0.012, Kruskal-Wallis test).

\ud \ud

Conclusion: Allopurinol treatment is well tolerated and attenuates the rise in intercellular adhesion molecule-1 levels seen after stroke. Uric acid levels were lowered with high doses. These findings support further evaluation of allopurinol as a preventive measure after stroke.

  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Dawson J, Walters MR. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol. 2006;62:633- 644.
    • 2. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and vascular events after acute stroke. Stroke. 2003;34:1951-1957.
    • 3. Cherubini A, Polidori MC, Bregnocchi M, Pezzuto S, Cecchetti R, Ingegni T, di Iorio A, Senin U, Mecocci P. Antioxidant profile and early outcome in stroke patients. Stroke. 2003;31:2295-2300.
    • 4. Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke. 2002;33:1048 -1052.
    • 5. Høiggen A, Alderman M, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlo¨ f B; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65: 1041-1049.
    • 6. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJV, Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000;106:221-226.
    • 7. Dawson J, Quinn TQ, Walters MR. Xanthine oxidase inhibition-a new paradigm in management of cardiovascular risk. Curr Med Chem. 2007; 14:1879 -1886.
    • 8. Okamoto H, Mizuno K, Hori T. Monocytes-derived multinucleated giant cells and sarcoidosis. J Dermatol Sci. 2003;31:119 -128.
    • 9. Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke. 2007;38:2173.
    • 10. George J, Carr E, Davies J, Belch JJF, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508 -2516.
    • 11. Martz D, Rayos G, Schielke GP, Betz AL. Allopurinol and dimethylthiourea reduce brain infarction following middle cerebral artery occlusion in rats. Stroke. 1989;20:488 - 494.
    • 12. Bitsch A, Klene W, Murtada L, Prange H, Rieckmann P. A longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke. 1998;29:2129 -2135.
    • 13. Sanchez-Moreno C, Dashe JF, Scott T, Thaler D, Folstein MF, Martin A. Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke. 2004;35: 163-168.
    • 14. Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE. Systemic complement activation following human acute ischemic stroke. Clin Exp Immunol. 2004;137:117-122.
    • 15. Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A. Inflammation-mediated damage in progressing lacunar infarctions. Stroke. 2002;33:982-987.
    • 16. Romano M, Mezetti A, Marulli C, Ciabattoni G, Febo F, DiLenno S, Roccaforte S, Vigneri S, Nubile G, Milani M, Davi G. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholeterolemic patients: role of nitric oxide. J Investig Med. 2000;48:183-189.
    • 17. Mocco J, Choudhri TF, Mack WJ, Laufer I, Lee J, Kiss S, Poisik A, Quest DO, Solomon R, Connoly SE. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery. 2001;48:718 -722.
    • 18. Consoli D, Di Carlo A, Inzitari D, De Lucia D, Lamassa M, D'Avino M, Baldereschi M, Muto M, Mandarino A, Napolitano M, Romano MF, Caruso D. Subcortical ischemic changes in young hypertensive patients: frequency, effect on cognitive performance and relationship with markers of endothelial and haemostatic activation. Eur J Neurol. 25 Sept 2007 [Epub ahead of print].
    • 19. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004;291: 1978 -1986.
    • 20. Song Y, Manson JE, Tinker L, Rifai N, Cook NR, Hu FB, Hotamisligil GS, Ridker PM, Rodriguez BL, Margolis KL, Oberman A, Liu S. Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. Diabetes. 2007;56:1898 -1904.
    • 21. Chien KL, Chen MF, Hsu HC, Chang WT, Su TC, Lee YT, Hu FB. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem. 2008;54:310 -316.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article